Trial reportHaematologica2016
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.
Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 81 citations in OpenAlex.
- Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials.European journal of haematology · 2026Trial
- Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.Acta haematologica · 2026Trial
- Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.Bone marrow transplantation · 2025Trial
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.Journal of hematology & oncology · 2017Trial
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Journal of hematology & oncology · 2017Trial
- Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.International journal of cancer · 2026Review
- Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study.Blood cancer journal · 2026Article
- Development Trends of Janus Kinase Inhibitors (JAKi) Over Three Decades: From Common to Rare Diseases.Drug design, development and therapy · 2026Review
- Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan.PloS one · 2026Article
- Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.Future oncology (London, England) · 2025Observational
- Increased Rate of Anemia and Discontinuation in Older Patients with Myelofibrosis Treated with Ruxolitinib.Journal of clinical medicine · 2025Article
- Emerging Therapeutic Approaches for Anemia in Myelofibrosis.Current hematologic malignancy reports · 2025Review
- Article
- Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.EJHaem · 2025Article
- Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib.Oncology and therapy · 2025Article
- Review
- Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data.Journal of managed care & specialty pharmacy · 2024Article
- Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies.Discover oncology · 2024Review
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices.Current hematologic malignancy reports · 2024Review
- Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.Haematologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 5 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.